E Fund Management Co. Ltd. Sells 865 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

E Fund Management Co. Ltd. lowered its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 10.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,395 shares of the company’s stock after selling 865 shares during the period. E Fund Management Co. Ltd.’s holdings in Vera Therapeutics were worth $268,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its holdings in Vera Therapeutics by 20.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after purchasing an additional 688 shares during the period. Cetera Advisors LLC acquired a new stake in shares of Vera Therapeutics in the first quarter valued at approximately $235,000. Capstone Investment Advisors LLC bought a new position in shares of Vera Therapeutics during the 1st quarter worth approximately $248,000. Pale Fire Capital SE acquired a new position in shares of Vera Therapeutics during the 4th quarter worth approximately $252,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Vera Therapeutics by 30.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock valued at $272,000 after acquiring an additional 1,737 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Insider Activity

In related news, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total value of $585,937.50. Following the transaction, the chief executive officer now owns 307,972 shares in the company, valued at $11,548,950. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 21.70% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on VERA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 price objective on shares of Vera Therapeutics in a research report on Monday. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Buy” and an average target price of $51.75.

Vera Therapeutics Price Performance

NASDAQ:VERA opened at $41.99 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -20.48 and a beta of 0.99. Vera Therapeutics, Inc. has a 52 week low of $9.24 and a 52 week high of $50.78. The firm’s 50-day simple moving average is $37.26 and its 200 day simple moving average is $39.09.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). As a group, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.